Herpes zoster infection as an immune reconstitution inflammatory syndrome in HIV-seropositive subjects: a review (Q36866720)

16 August 2017

1 reference

title

Herpes zoster infection as an immune reconstitution inflammatory syndrome in HIV-seropositive subjects: a review (English)

1 reference

immune reconstitution inflammatory syndrome

16 August 2017

1 reference

1 reference

Liviu Feller

1

1 reference

PubMed ID

17604657

16 August 2017

Neil H Wood

series ordinal

2

1 reference

PubMed ID

17604657

16 August 2017

Johan Lemmer

series ordinal

3

1 reference

16 August 2017

29 June 2007

1 reference

Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics

16 August 2017

1 reference

16 August 2017

104

1 reference

16 August 2017

4

1 reference

16 August 2017

455-460

1 reference

Immunorestitution disease involving the innate and adaptive response

16 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Immune restoration disease in HIV-infected patients after antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Herpes zoster as an immune restoration disease in AIDS patients during therapy including protease inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Immune restoration disease after antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Dermatological immune restoration syndrome: does it exist?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Herpes zoster as an immune reconstitution disease after initiation of combination antiretroviral therapy in patients with human immunodeficiency virus type-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Assessment of Type 1 and Type 2 Cytokines in HIV Type 1-Infected Individuals: Impact of Highly Active Antiretroviral Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Immunologic reconstitution in the acquired immunodeficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Impaired production of lymphokines and immune (gamma) interferon in the acquired immunodeficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Selective defects in cytomegalovirus- and mitogen-induced lymphocyte proliferation and interferon release in patients with acquired immunodeficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Relation between Changes in Cellular Load, Evolution of Viral Phenotype, and the Clonal Composition of Virus Populations in the Course of Human Immunodeficiency Virus Type 1 Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

The IL4- induced switch of CD8+ T cells to a TH2 phenotype and its possible relationship to the onset of AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

TH1 and TH2 cytokine production by peripheral blood mononuclear cells from HIV-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

The Th1-Th2 hypothesis of HIV infection: new insights

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

A TH1-->TH2 switch is a critical step in the etiology of HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Type 1/Type 2 immunity in infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Viral dynamics in human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Decline in the rate of oral opportunistic infections following introduction of highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Clinical and immunological benefits from highly active antiretroviral therapy in spite of limited viral load reduction in HIV type 1 infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Preliminary evidence for partial restoration of immune function in HIV type 1 infection with potent antiretroviral therapies: clues from the Fourth Conference on Retroviruses and Opportunistic Diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

T Cell Telomere Length in HIV-1 Infection: No Evidence for Increased CD4+ T Cell Turnover

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

CD8+ T cells suppress human immunodeficiency virus replication by inhibiting viral transcription

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Viral infections of the head and neck among HIV-seropositive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Alveolar bone necrosis and tooth exfoliation secondary to herpes zoster in the setting of HIV/AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

7 January 2021

Varicella-zoster virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Herpes zoster in HIV-1-infected patients in the era of highly active antiretroviral therapy: a prospective observational study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Immune Reconstitution Syndrome in HIV: Validating a Case Definition and Identifying Clinical Predictors in Persons Initiating Antiretroviral Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

Opportunistic infections occurring during highly active antiretroviral treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2007.02.001

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.TRIPLEO.2007.02.001

1 reference

16 August 2017

1 reference

PubMed ID

17604657